Bleomycin 11056-06-7
| Systematic (IUPAC) name: |
(3-{[(2'-{(5S,8S,9S,10R,13S)-15-{6-amino-2- [(1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl] -5-methylpyrimidin-4-yl}-13-[{[(2R,3S,4S,5S,6S)-3- {[(2R,3S,4S,5R,6R)-4-(carbamoyloxy)-3,5-dihydroxy-6- (hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy} -4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy} (1H-imidazol-5-yl)methyl]-9-hydroxy-5-[(1R)-1-hydroxyethyl]-8,10-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazapentadec-1-yl}-2,4'-bi-1,3- thiazol-4-yl)carbonyl]amino}propyl)(dimethyl)sulfonium |
| Bleomycin CAS number: |
11056-06-7 |
| ATC code: |
L01DC01 |
| PubChem: |
456190 |
| DrugBank: |
APRD00453 |
| Formula: |
C55H84N17O21 |
| Molecular mass: |
1415.551 g/mol |
| Bleomycin Assay/Purity: |
Typically NLT 98% |
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
